Tags

Type your tag names separated by a space and hit enter

Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
Chest. 2006 Sep; 130(3):647-56.Chest

Abstract

STUDY OBJECTIVE

To examine the effect of fluticasone propionate, 250 microg/salmeterol, 50 microg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of exercise performance in patients with COPD.

DESIGN

This was a randomized, double-blind, parallel-group study.

PATIENTS

Eligible patients were > or = 40 years old with a diagnosis of COPD, prealbuterol FEV(1) < 70% of predicted, FEV1/FVC ratio > or = 0.70, and functional residual capacity (FRC) > or = 120% of predicted normal.

INTERVENTIONS

Patients were randomized to FSC 250/50; salmeterol, 50 microg; or placebo twice daily for 8 weeks. Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations were compared. The primary comparison was FSC 250/50 with placebo. The salmeterol group was included for exploratory comparisons with FSC 250/50.

RESULTS

A total of 185 patients (mean baseline FEV1 of 41% predicted) were enrolled. At rest, FSC 250/50 significantly reduced postdose FRC and increased inspiratory capacity (IC) compared with placebo (differences of - 0.35 +/- 0.12 L and 0.33 +/- 0.06 L [mean +/- SE], respectively, at week 8; p > or = 0.003) and increased exercise endurance time (difference, 132 +/- 45 s; p = 0.004). At a standardized time during exercise (isotime), FSC 250/50 increased postdose IC by 0.20 +/- 0.05 L over placebo with associated improvements in tidal volume and minute ventilation (p < 0.05 vs placebo at week 8). Improvement in exercise time was significantly correlated with the increase in IC (r = 0.45, p < 0.001) but not FEV1 (r = 0.23, p = 0.08). Predose comparisons of FSC 250/50 with salmeterol and placebo favored FSC 250/50.

CONCLUSION

We conclude that FSC 250/50 decreases lung hyperinflation at rest and during exercise with an associated increase in exercise endurance time when compared with placebo.

Authors+Show Affiliations

Queen's University, Kingston, ON, Canada. odonnell@post.queensu.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16963658

Citation

O'Donnell, Denis E., et al. "Effect of Fluticasone Propionate/salmeterol On Lung Hyperinflation and Exercise Endurance in COPD." Chest, vol. 130, no. 3, 2006, pp. 647-56.
O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130(3):647-56.
O'Donnell, D. E., Sciurba, F., Celli, B., Mahler, D. A., Webb, K. A., Kalberg, C. J., & Knobil, K. (2006). Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest, 130(3), 647-56.
O'Donnell DE, et al. Effect of Fluticasone Propionate/salmeterol On Lung Hyperinflation and Exercise Endurance in COPD. Chest. 2006;130(3):647-56. PubMed PMID: 16963658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. AU - O'Donnell,Denis E, AU - Sciurba,Frank, AU - Celli,Bartolome, AU - Mahler,Donald A, AU - Webb,Katherine A, AU - Kalberg,Chris J, AU - Knobil,Katharine, PY - 2006/9/12/pubmed PY - 2006/10/7/medline PY - 2006/9/12/entrez SP - 647 EP - 56 JF - Chest JO - Chest VL - 130 IS - 3 N2 - STUDY OBJECTIVE: To examine the effect of fluticasone propionate, 250 microg/salmeterol, 50 microg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures of exercise performance in patients with COPD. DESIGN: This was a randomized, double-blind, parallel-group study. PATIENTS: Eligible patients were > or = 40 years old with a diagnosis of COPD, prealbuterol FEV(1) < 70% of predicted, FEV1/FVC ratio > or = 0.70, and functional residual capacity (FRC) > or = 120% of predicted normal. INTERVENTIONS: Patients were randomized to FSC 250/50; salmeterol, 50 microg; or placebo twice daily for 8 weeks. Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations were compared. The primary comparison was FSC 250/50 with placebo. The salmeterol group was included for exploratory comparisons with FSC 250/50. RESULTS: A total of 185 patients (mean baseline FEV1 of 41% predicted) were enrolled. At rest, FSC 250/50 significantly reduced postdose FRC and increased inspiratory capacity (IC) compared with placebo (differences of - 0.35 +/- 0.12 L and 0.33 +/- 0.06 L [mean +/- SE], respectively, at week 8; p > or = 0.003) and increased exercise endurance time (difference, 132 +/- 45 s; p = 0.004). At a standardized time during exercise (isotime), FSC 250/50 increased postdose IC by 0.20 +/- 0.05 L over placebo with associated improvements in tidal volume and minute ventilation (p < 0.05 vs placebo at week 8). Improvement in exercise time was significantly correlated with the increase in IC (r = 0.45, p < 0.001) but not FEV1 (r = 0.23, p = 0.08). Predose comparisons of FSC 250/50 with salmeterol and placebo favored FSC 250/50. CONCLUSION: We conclude that FSC 250/50 decreases lung hyperinflation at rest and during exercise with an associated increase in exercise endurance time when compared with placebo. SN - 0012-3692 UR - https://www.unboundmedicine.com/medline/citation/16963658/Effect_of_fluticasone_propionate/salmeterol_on_lung_hyperinflation_and_exercise_endurance_in_COPD_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(15)52774-8 DB - PRIME DP - Unbound Medicine ER -